Arvinas, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARVN | PRTA | GLUE | CCCC | ALEC | DSGN | |
|---|---|---|---|---|---|---|
| Market cap | 486.01M | 430.72M | 923.09M | 383.84M | 254.58M | 665.24M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.3 | -6.4 | -5.9 | -3.4 | -3.1 | -6.6 |
| Price/book | 0.9 | 1.5 | 1.9 | 1.6 | -25.6 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −25.80% | −16.77% | −16.83% | +31.09% | +75.38% | +54.73% |
| Today | +4.65% | +2.19% | +3.94% | −2.80% | +11.22% | +2.80% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARVN news ›Arvinas Starts ARV-6723 Dosing, Reports $558.9 Million in Liquidity
Arvinas expects initial monotherapy data for ARV-6723 in the second half of 2027, while ARV-393 data are planned for a December hematology meeting. Arvinas has begun dosing patients in the monotherapy cohort of its ARV-6723 Phase 1/2…
Arvinas outlines cash runway into the second half of 2028 while targeting multiple Phase I readouts through 2027
Arvinas Q3 2026 earnings insights: key pipeline updates, ARV-393 and ARV-102 timelines, cash runway to 2028, and risks to watch. Earnings Call Insights: Arvinas, Inc. (ARVN) Q3 2026 "I'll start by reiterating our commitment to prioritizing…
Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
Arvinas to Present Preliminary Clinical Data from Early GlobeNewswire
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation - - Reaffirmed commitment to share clinical data from three Phase 1 programs - ARV-393,…
Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Randy Teel - CEO, President & DirectorAngela Cacace - Chief Scientific OfficerAndrew Saik - CFO & Treasurer Edward Tenthoff - Piper Sandler & Co., Research…
More from 1 other outlet
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinsonâs Disease and Movement Disorders® Arvinas to Present Novel Biomarker Data from…
Arvinas presents data from clinical trial of ARV-102
Arvinas (ARVN) presented novel data from a Phase 1 clinical trial of ARV-102, an investigational PROteolysis TArgeting Chimera, or PROTAC, degra... Arvinas presents data from clinical trial of ARV-102 Arvinas (ARVN) presented novel data…
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO). In a report released today, Sachin Jain from Bank of America Securities…
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation – – Nominations open November 1, 2026, and close December 31, 2026; winner to be recognized in mid-2027 – First…
Arvinas takes its Parkinson’s degrader to Seoul
Five minutes. That’s the slot Arvinas was given to present late-breaking data from its Phase 1 trial of ARV-102 in people with Parkinson’s disease. The stage was the 2026 International Congress of Parkinson’s Disease and Movement Disorders…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com3
- seekingalpha.com2
- defenseworld.net1
- manilatimes.net1
- marketbeat.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.